Silexion Therapeutics Corp
SLXN· Nasdaq
SLXNSilexion Therapeutics Corp
Filed Nov 14, 2024 · 10-Q · 45 days after period end · 0001178913-24-003686
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Income | -$11.86M | -$809.00K |
| EPS Diluted | $274.25 | $0.78 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Silexion Therapeutics Corp · CIK 2022416 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end
